These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35877083)

  • 1. Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE.
    Gong J; Posadas EM
    JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35877083
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough?
    Turco F; Tucci M; Buttigliero C
    Minerva Urol Nephrol; 2021 Dec; 73(6):870-872. PubMed ID: 35144376
    [No Abstract]   [Full Text] [Related]  

  • 3. Researchers probe consequences of androgen deprivation for prostate cancer.
    Friedrich MJ
    JAMA; 2006 Nov; 296(19):2305-6. PubMed ID: 17105787
    [No Abstract]   [Full Text] [Related]  

  • 4. Hormone Treatment of Prostate Cancer:: Evidence for Usage and Safety.
    Labban M; Alkassis M; Alkhatib K; Briggs L; Cole AP; Kibel AS; Trinh QD
    Urol Clin North Am; 2022 May; 49(2):309-321. PubMed ID: 35428436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Associated with Osteoporosis Management Among Veterans Who Received Androgen Deprivation Therapy for Prostate Cancer.
    Solimeo SL; Lund BC; McCoy KD; Sarrazin MV; Hoffman R
    J Gen Intern Med; 2021 Oct; 36(10):3270-3272. PubMed ID: 33483816
    [No Abstract]   [Full Text] [Related]  

  • 6. Unsafe testosterone-based dosing regimen of androgen deprivation therapy in patients with locally advanced or metastatic prostate cancer: a prematurely ended randomized controlled trial (MIDAS-trial).
    Mulder MB; Birnie E; van Dijck-van Boetzelaer C; van de Geijn GJ; Boevé E; Westerman EM; Hamberg P
    Acta Oncol; 2021 Apr; 60(4):539-543. PubMed ID: 33356721
    [No Abstract]   [Full Text] [Related]  

  • 7. Cognitive function in prostate cancer patients on androgen deprivation therapy: A case-control study.
    Atallah P; Kanaan RA; Russell N; Allebone J; Grossmann M
    Gen Hosp Psychiatry; 2020; 67():152-153. PubMed ID: 32451089
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial Comment to Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi-institutional Japan-wide database.
    Hatakeyama S; Ohyama C
    Int J Urol; 2021 May; 28(5):591-592. PubMed ID: 33663016
    [No Abstract]   [Full Text] [Related]  

  • 9. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update.
    Owen PJ; Daly RM; Livingston PM; Fraser SF
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):137-145. PubMed ID: 28117386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy.
    Chan JSK; Lee YHA; Liu K; Hui JMH; Dee EC; Ng K; Satti DI; Tang P; Tse G; Ng CF
    Eur J Clin Invest; 2023 Apr; 53(4):e13932. PubMed ID: 36468787
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: androgen deprivation therapy: impact on quality of life and cardiovascular health.
    Shah SI; Cafferty FH; Langley RE; Abel PD
    J Sex Med; 2014 Jan; 11(1):314-5. PubMed ID: 24112553
    [No Abstract]   [Full Text] [Related]  

  • 12. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
    Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
    J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry.
    Kwon DH; Vashisht R; Borno HT; Aggarwal RR; Small EJ; Butte AJ; Huang FW
    Ann Oncol; 2021 May; 32(5):678-679. PubMed ID: 33571636
    [No Abstract]   [Full Text] [Related]  

  • 14. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
    Koontz BF; Lee WR
    Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
    Rübben H
    Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Pitts WR
    J Urol; 2003 Dec; 170(6 Pt 1):2392-3; author reply 2393-4. PubMed ID: 14634434
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of intermittent androgen deprivation in prostate cancer.
    Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U
    BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostate cancer treatment and the relationship of androgen deprivation therapy to cognitive function.
    Reiss AB; Saeedullah U; Grossfeld DJ; Glass AD; Pinkhasov A; Katz AE
    Clin Transl Oncol; 2022 May; 24(5):733-741. PubMed ID: 34743290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
    Gulley JL; Aragon-Ching JB; Steinberg SM; Hussain MH; Sartor O; Higano CS; Petrylak DP; Chatta GS; Arlen PM; Figg WD; Dahut WL
    J Urol; 2008 Oct; 180(4):1432-7; discussion 1437. PubMed ID: 18710748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to the letter to editor: Neurocognitive deficits attributed to androgen deprivation therapy in patients with prostate cancer should be reconsidered.
    Ihrig A; Pernt PM; Zschäbitz S; Huber J; Friederich HC; Bugaj TJ; Maatouk I
    Int Urol Nephrol; 2024 Jan; 56(1):145. PubMed ID: 37698710
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.